Mektovi

Description

Mektovi is intended for the treatment of melanoma in adult patients over 18 years of age with a mutation in the gene responsible for the production of the BRAF protein, with damage to other organs and systems, or when the tumor cannot be removed surgically.

Melanoma is one of the most aggressive malignant skin diseases, characterized by high mortality rates.

The combination of encorafenib and binimetinib opens up new possibilities in the treatment of unresectable and metastatic melanoma with a mutation in the BRAF V600 gene and reduces the risk of disease progression and death in this group of patients.

Active ingredient: binimetinib

Prescription medicine